Iovance Biotherapeutics (NASDAQ:IOVA) Now Covered by Cowen

Analysts at Cowen began coverage on shares of Iovance Biotherapeutics (NASDAQ:IOVA) in a report issued on Monday, AnalystRatings.com reports. The firm set a “buy” rating on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the stock. BidaskClub cut shares of Iovance Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, November 21st. JMP Securities assumed coverage on shares of Iovance Biotherapeutics in a research note on Wednesday, December 18th. They set an “outperform” rating and a $38.00 price target for the company. ValuEngine lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Finally, Chardan Capital restated a “buy” rating and set a $33.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $31.73.

Iovance Biotherapeutics stock opened at $23.88 on Monday. Iovance Biotherapeutics has a 52 week low of $8.26 and a 52 week high of $29.67. The company’s 50 day moving average price is $26.26 and its two-hundred day moving average price is $22.79. The company has a quick ratio of 10.61, a current ratio of 10.61 and a debt-to-equity ratio of 0.02. The stock has a market cap of $3.02 billion, a P/E ratio of -18.80 and a beta of 2.07.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.01). On average, equities analysts anticipate that Iovance Biotherapeutics will post -1.5 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Coastal Investment Advisors Inc. increased its stake in shares of Iovance Biotherapeutics by 2.9% during the 3rd quarter. Coastal Investment Advisors Inc. now owns 29,390 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 815 shares during the last quarter. Strs Ohio grew its stake in Iovance Biotherapeutics by 0.7% in the 3rd quarter. Strs Ohio now owns 127,800 shares of the biotechnology company’s stock valued at $2,325,000 after buying an additional 900 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in Iovance Biotherapeutics by 14.9% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock valued at $189,000 after buying an additional 1,000 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in Iovance Biotherapeutics in the 2nd quarter valued at approximately $29,000. Finally, Tocqueville Asset Management L.P. grew its stake in Iovance Biotherapeutics by 1.2% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 128,605 shares of the biotechnology company’s stock valued at $2,341,000 after buying an additional 1,550 shares in the last quarter. Institutional investors own 98.10% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Recommended Story: How prevalent are 12b-1 fees?

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.